India Pharma Expo 2027
SAS Digital Sovereignty
Gaurav Gupta

In this exclusive conversation, Gaurav Gupta, Co-Founder & CEO of CarePay, shares his perspectives with Dr. Asawari Savant of Elets News Network (ENN) on the evolving role of healthcare financing, AI-led innovation and digital infrastructure in making quality healthcare more accessible and affordable. The discussion also explores India’s healthcare innovation priorities in the context of Make in India and Viksit Bharat 2047. Edited excerpts 


India’s healthcare challenge is not only the cost of treatment, but the timing of when patients can access funds. Do you believe healthcare financing is becoming a form of healthcare infrastructure in itself? And if so, how should it be integrated into the care journey without influencing clinical decisions or encouraging unnecessary consumption?

Healthcare financing is increasingly becoming an essential part of healthcare infrastructure. Access to quality treatment depends not just on the availability of doctors, hospitals or medicines, but also on whether patients can afford to access them when they need to.


In India, a significant share of healthcare expenditure is still paid out of pocket. Even when patients are medically ready to proceed with treatment, a large upfront payment can lead to delays, deferred procedures or abandoned treatment plans. Financing can help bridge this gap by converting a large one-time expense into manageable monthly payments.

However, financing must remain separate from clinical decision-making. The doctor should determine the appropriate treatment based on medical need, while financing should simply provide patients with a way to manage its cost. Patients must have access to transparent terms, multiple financing options and a clear understanding of their repayment obligations.

At CarePay, we believe financing should be embedded at the point of care as an enabling layer, not a sales mechanism. The objective is to make clinically recommended treatment financially accessible without influencing what treatment a patient receives.

As healthcare financing platforms scale, they increasingly sit at the intersection of patients, hospitals, insurers, pharmacies and lenders. What kind of model can balance commercial viability with responsible access, especially when affordability, credit risk and patient vulnerability all come into play?

The most sustainable model is one where every stakeholder creates value without compromising the patient’s interests.

Healthcare providers need better treatment acceptance and predictable cash flows. Patients need affordable and transparent payment options. Lenders need responsible credit origination and manageable risk. Insurers need solutions that complement existing coverage. A financing platform should bring these stakeholders together through a model that aligns their interests.

This requires moving beyond simply distributing loans. Platforms must understand the nature of healthcare expenditure, treatment costs, patient affordability and repayment capacity. Multiple lending partnerships can help provide patients with suitable options rather than forcing them into a single credit product.

At CarePay, we believe responsible healthcare financing must be built around three principles: affordability, transparency and suitability. Credit decisions should account for repayment capacity, loan terms should be clearly communicated, and patients should never feel pressured into borrowing.

Commercial viability will come from building trust with healthcare providers and patients, reducing payment friction and improving operational efficiency. The long-term opportunity lies in creating a financing ecosystem where access improves while credit risk remains responsibly managed.

AI and advanced technologies are increasingly being used for risk assessment, predictive analytics and faster decision-making. Where do you see AI creating the greatest impact across healthcare, and how can the industry ensure that technology improves access without compromising trust, privacy or fairness?

We believe AI will have its greatest near-term impact in making healthcare more efficient, personalised and accessible. While much of the conversation focuses on AI-led diagnosis, there is an equally important opportunity in improving the operational layers surrounding patient care.

From identifying patients who need timely follow-ups to predicting affordability barriers, improving appointment management, simplifying insurance and financing assessments, and supporting healthcare teams with better information, AI can help reduce friction across the patient journey.

At CarePay, we see this opportunity in using AI to make healthcare financing faster and more contextual. We have developed an in-house AI payment  processing bot – Careena AI which can help assess available financial information, identify suitable financing pathways and reduce the time patients spend navigating payment options.

However, healthcare data is particularly sensitive. AI adoption must be supported by informed consent, strong data security, clear usage policies and human oversight. Models must also be regularly evaluated for bias so that decisions do not disadvantage patients based on income, geography, age or other characteristics.

Technology should augment human judgement, not replace it. Ultimately, the success of AI in healthcare should be measured not by how much it automates, but by how much it improves patient outcomes, access and trust.

When we talk about Make in India in healthcare, the conversation often centres on medicines and medical devices. Should the next phase also focus on building

indigenous digital-health and healthcare-financing infrastructure? What would it take to create scalable Indian solutions that can eventually serve global markets?

Absolutely. India’s next phase of healthcare innovation should extend beyond manufacturing medicines and medical devices to building the digital and financial infrastructure that makes healthcare accessible.

India has a unique opportunity to develop technology-led solutions for challenges that are common across emerging markets: fragmented healthcare systems, high out-of-pocket expenditure, limited access to formal credit and gaps in patient information.

We need indigenous platforms across health data infrastructure, patient engagement, healthcare payments, financing, insurance integration and AI-led decision support. These should be interoperable, secure and designed around the realities of Indian healthcare, including multiple languages, diverse income groups and varying levels of digital access.

Healthcare financing is one important part of this infrastructure. Building local solutions that understand treatment-specific costs, patient affordability and the lending ecosystem can help address gaps that generic financial products may not fully serve.

To scale globally, Indian solutions must demonstrate measurable improvements in access, affordability and operational efficiency. They should also be built on adaptable technology and global standards rather than being restricted to one market.

As India moves towards Viksit Bharat 2047, what should an ideal healthcare ecosystem look like from the patient’s perspective? How important will affordability, digital access and innovative financing models be in achieving more equitable access to quality healthcare?

From a patient’s perspective, an ideal healthcare ecosystem is one where access to quality treatment is determined by medical need rather than financial circumstances or geographical limitations.

By 2047, patients should be able to access reliable healthcare providers, understand the cost of treatment upfront, receive transparent information about their options and navigate the entire care journey with minimal friction.

Insurance will remain critical in protecting households against major medical expenses. However, insurance alone may not address every healthcare expense, particularly planned procedures, specialised treatments and costs that fall outside policy coverage. This is where a combination of savings, insurance and responsible financing becomes important.

Digital infrastructure will play a major role in connecting patients with providers, improving continuity of care and making healthcare services more accessible. At the same time, solutions must remain inclusive of people who may not have consistent access to smartphones, digital literacy or formal financial services.

At CarePay, we believe affordability needs to be treated as an integral part of healthcare access. A developed healthcare ecosystem should ensure that patients are not forced to postpone clinically recommended treatment simply because they cannot arrange the entire amount upfront.

The measure of progress towards Viksit Bharat should ultimately be how many more people can access timely, quality and affordable healthcare.

Also read: The Rise of Intelligent, Digitally Enabled & Net Zero-Ready Healthcare Infrastructure

India Pharma Expo 2027 brings together pharma companies, healthcare providers, technology companies, startups, policymakers and investors. What kinds of collaborations should a platform like this enable to connect pharmaceutical innovation with affordability, financing and ultimately better patient access?

Platforms like India Pharma Expo should encourage collaborations that connect innovation at the product level with affordability and access at the patient level.

A new medicine, therapy or medical technology creates meaningful impact only when patients who need it can actually access and afford it. This requires pharmaceutical companies to work more closely with healthcare providers, insurers, financing platforms and technology companies.

For example, pharmaceutical companies and financing providers can explore patient assistance programmes and structured payment solutions for high-cost or long-duration treatments. Hospitals and technology platforms can collaborate to improve cost transparency and integrate financing options into the patient journey. Insurers and lenders can work together to address gaps between policy coverage and actual treatment expenses.

At CarePay, we see significant potential in treatment-specific financing and protection models. Our HopeGuard offering in IVF, for instance, combines no-cost EMI financing with treatment-linked financial protection, demonstrating how financing and protection can work together to make specialised treatments more accessible.

India Pharma Expo can be a catalyst for such partnerships by bringing stakeholders together to develop, test and scale solutions around real patient affordability challenges.

The industry needs to move from discussing innovation in isolation to building collaborative models that ensure innovation reaches the patients it is intended to serve.


Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!

Related Interview


whatsapp--v1 JOIN US
whatsapp--v1